Estrogen receptor modulators and down regulators: optimal use in postmenopausal women with breast cancer.

摘要: Endocrine treatments have been used in breast cancer since 1896, when Beatson reported on the results of oophorectomy for advanced cancer. In second half last century, different endocrine-based compounds were developed and, this review, role selective estrogen receptor modulators (SERMs) and down regulators (SERDs) postmenopausal setting are discussed. Tamoxifen is most investigated widely representative these agents, has introduced disease, neoadjuvant adjuvant setting, prevention disease. Its challenged recent years by introduction third-generation aromatase inhibitors that proven higher activities than tamoxifen with toxicity patterns. Several other SERMs investigated, but none clearly superior to tamoxifen. SERDs act as pure antagonists should compare favourably For time being, they treatment cancers their settings still needs investigation. The increased use first-line endocrine therapy resulted new discussions regarding or may play sequencing therapies hormone-sensitive remains a very important research issue.